SG11201911639TA - Methods and compositions for reducing the immunogenicity of chimeric notch receptors - Google Patents
Methods and compositions for reducing the immunogenicity of chimeric notch receptorsInfo
- Publication number
- SG11201911639TA SG11201911639TA SG11201911639TA SG11201911639TA SG11201911639TA SG 11201911639T A SG11201911639T A SG 11201911639TA SG 11201911639T A SG11201911639T A SG 11201911639TA SG 11201911639T A SG11201911639T A SG 11201911639TA SG 11201911639T A SG11201911639T A SG 11201911639TA
- Authority
- SG
- Singapore
- Prior art keywords
- immunogenicity
- compositions
- reducing
- methods
- notch receptors
- Prior art date
Links
- 102000005650 Notch Receptors Human genes 0.000 title 1
- 108010070047 Notch Receptors Proteins 0.000 title 1
- 230000005847 immunogenicity Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762603993P | 2017-06-19 | 2017-06-19 | |
US201762556765P | 2017-09-11 | 2017-09-11 | |
PCT/US2018/038218 WO2018236825A1 (en) | 2017-06-19 | 2018-06-19 | Methods and compositions for reducing the immunogenicity of chimeric notch receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201911639TA true SG11201911639TA (en) | 2020-01-30 |
Family
ID=64656151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201911639TA SG11201911639TA (en) | 2017-06-19 | 2018-06-19 | Methods and compositions for reducing the immunogenicity of chimeric notch receptors |
Country Status (16)
Country | Link |
---|---|
US (3) | US11325957B2 (en) |
EP (1) | EP3641791A1 (en) |
JP (2) | JP7106581B2 (en) |
KR (2) | KR102489939B1 (en) |
CN (1) | CN110753552B (en) |
AU (2) | AU2018289383B2 (en) |
BR (1) | BR112019026309A2 (en) |
CA (1) | CA3065549C (en) |
CO (1) | CO2019013786A2 (en) |
IL (1) | IL271144A (en) |
MX (1) | MX2019015513A (en) |
NZ (1) | NZ759712A (en) |
SA (1) | SA519410835B1 (en) |
SG (1) | SG11201911639TA (en) |
TW (1) | TWI826379B (en) |
WO (1) | WO2018236825A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210008840A (en) * | 2018-04-10 | 2021-01-25 | 스티흐팅 산퀸 불드포르지닝 | Chimeric notch receptor |
CN111826398A (en) * | 2019-04-16 | 2020-10-27 | 常州费洛斯药业科技有限公司 | Engineering plasmid system for displaying and detecting interaction of membrane protein between living cells |
CN114728174A (en) * | 2019-09-24 | 2022-07-08 | 加利福尼亚大学董事会 | Receptors with heterologous transmembrane domains |
EP4267623A1 (en) | 2020-12-24 | 2023-11-01 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3853515T3 (en) | 1987-05-21 | 2005-08-25 | Micromet Ag | MULTIFUNCTIONAL PROTEINS WITH SPECIFIC OBJECTIVES. |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
ATE207080T1 (en) | 1991-11-25 | 2001-11-15 | Enzon Inc | MULTIVALENT ANTIGEN-BINDING PROTEINS |
GB0015119D0 (en) | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
EP2193143B1 (en) * | 2007-08-23 | 2016-06-08 | The Trustees of Columbia University in the City of New York | Compositions of humanized notch fusion proteins and methods of treatment |
ES2868247T3 (en) | 2013-02-15 | 2021-10-21 | Univ California | Chimeric antigen receptor and methods of using it |
WO2016138034A1 (en) | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
IL304088A (en) | 2016-01-11 | 2023-08-01 | Univ Leland Stanford Junior | Chimeric Proteins- Containing Systems and Uses Thereof in Regulating Gene Expression |
CN109843929A (en) * | 2016-08-23 | 2019-06-04 | 加利福尼亚大学董事会 | The cleavable chimeric polyeptides of proteolysis and its application method |
EP3755712A1 (en) | 2018-02-21 | 2020-12-30 | Cell Design Labs, Inc. | Chimeric transmembrane receptors and uses thereof |
-
2018
- 2018-06-18 US US16/010,805 patent/US11325957B2/en active Active
- 2018-06-19 EP EP18745721.3A patent/EP3641791A1/en active Pending
- 2018-06-19 AU AU2018289383A patent/AU2018289383B2/en active Active
- 2018-06-19 KR KR1020217043321A patent/KR102489939B1/en active IP Right Grant
- 2018-06-19 CA CA3065549A patent/CA3065549C/en active Active
- 2018-06-19 JP JP2019569872A patent/JP7106581B2/en active Active
- 2018-06-19 TW TW107120999A patent/TWI826379B/en active
- 2018-06-19 MX MX2019015513A patent/MX2019015513A/en unknown
- 2018-06-19 CN CN201880039563.8A patent/CN110753552B/en active Active
- 2018-06-19 KR KR1020207001681A patent/KR102347296B1/en active IP Right Grant
- 2018-06-19 BR BR112019026309-8A patent/BR112019026309A2/en unknown
- 2018-06-19 NZ NZ759712A patent/NZ759712A/en unknown
- 2018-06-19 SG SG11201911639TA patent/SG11201911639TA/en unknown
- 2018-06-19 WO PCT/US2018/038218 patent/WO2018236825A1/en unknown
-
2019
- 2019-12-03 IL IL271144A patent/IL271144A/en unknown
- 2019-12-09 CO CONC2019/0013786A patent/CO2019013786A2/en unknown
- 2019-12-17 SA SA519410835A patent/SA519410835B1/en unknown
-
2021
- 2021-09-16 AU AU2021232761A patent/AU2021232761A1/en active Pending
-
2022
- 2022-04-08 US US17/716,636 patent/US20220363728A1/en active Pending
- 2022-04-08 US US17/716,630 patent/US20220372090A1/en active Pending
- 2022-05-02 JP JP2022075722A patent/JP2022105139A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220372090A1 (en) | 2022-11-24 |
JP7106581B2 (en) | 2022-07-26 |
KR20220003168A (en) | 2022-01-07 |
CN110753552B (en) | 2024-03-19 |
KR102347296B1 (en) | 2022-01-10 |
MX2019015513A (en) | 2020-09-10 |
KR20230015502A (en) | 2023-01-31 |
NZ759712A (en) | 2023-02-24 |
TW201905198A (en) | 2019-02-01 |
US20220363728A1 (en) | 2022-11-17 |
WO2018236825A1 (en) | 2018-12-27 |
AU2018289383A1 (en) | 2019-12-19 |
CO2019013786A2 (en) | 2020-01-17 |
AU2021232761A1 (en) | 2021-10-14 |
KR102489939B1 (en) | 2023-01-19 |
CN110753552A (en) | 2020-02-04 |
JP2020527032A (en) | 2020-09-03 |
BR112019026309A2 (en) | 2020-07-14 |
TWI826379B (en) | 2023-12-21 |
IL271144A (en) | 2020-01-30 |
CA3065549C (en) | 2023-08-22 |
SA519410835B1 (en) | 2023-03-19 |
EP3641791A1 (en) | 2020-04-29 |
AU2018289383B2 (en) | 2021-06-17 |
US20180362603A1 (en) | 2018-12-20 |
US11325957B2 (en) | 2022-05-10 |
KR20200019722A (en) | 2020-02-24 |
JP2022105139A (en) | 2022-07-12 |
CA3065549A1 (en) | 2018-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287718A (en) | Chimeric antigen receptors (cars), compositions and methods of use thereof | |
IL277079A (en) | Cartyrin compositions and methods for use | |
HK1259190A1 (en) | Methods and compositions relating to chimeric antigen receptors | |
HRP20192145T1 (en) | Carrier-antibody compositions and methods of making and using the same | |
HK1256726A1 (en) | Carrier-binding agent compositions and methods of making and using the same | |
PL3443096T3 (en) | Compositions and methods for selective expression of chimeric antigen receptors | |
IL268684A (en) | Compositions and methods for immunooncology | |
IL269590A (en) | Methods and compositions for reduction of immunogenicity | |
IL265438A (en) | Chimeric antigen receptors and compositions and methods of use thereof | |
IL271144A (en) | Methods and compositions for reducing the immunogenicity of chimeric notch receptors | |
ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
IL271680A (en) | Compositions and methods for inhibiting HMGB1 expression | |
GB2564510B (en) | Compositions and methods and uses relating thereto | |
SG11201803581VA (en) | Chimeric RSV, Immunogenic Compositions, and Methods of Use | |
GB201815402D0 (en) | Compositions and methods and uses relating thereto | |
IL274524A (en) | Compositions and methods for aquaculturing | |
GB2578519B (en) | Compositions and methods and uses relating thereto | |
HK1247136A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
PL3113774T3 (en) | Compositions of grapiprant and methods for using the same | |
PL3568203T3 (en) | Compounds and compositions | |
GB201716599D0 (en) | Compositions and methods and uses relating thereto | |
IL251588A0 (en) | Methods and compositions for increasing the potency of antifungal agents | |
SG11201912334YA (en) | Compositions and methods and uses relating thereto | |
GB201708965D0 (en) | Uses of cysteamine compositions |